- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03957954
Stem Cell Therapy for Limbal Stem Cell Deficiency
December 5, 2023 updated by: Sophie Deng, MD, PhD, University of California, Los Angeles
Safety and Feasibility of Cultivated Autologous Limbal Stem Cells (cLSC) for Limbal Stem Cell Deficiency
This phase I study will collect preliminary information on the activity and safety of cLSC.
We will investigate the ability to manufacture and transplant cLSC onto the cornea successfully at the time of surgery (feasibility), and have cLSC begin to populate the ocular surface (efficacy) without serious adverse events (safety).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
20 patients with severe to total Limbal Stem Cell Deficiency (LSCD) in one eye attributable to injury or ocular surgery.
The first 5 eyes will receive the cLSCs to determine the feasibility and safety.
Then the subsequent 15 eyes will be randomized into cLSC group and a scleral lens treatment (SCL) control group in a 2:1 ratio in blocks of 3 or 6 using a random number generator.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Clemence Bonnet, MD, PhD
- Phone Number: 310-825-6232
- Email: CBonnet@mednet.ucla.edu
Study Contact Backup
- Name: Maricarmen Contreras, BA
- Phone Number: 310-794-5593
- Email: MariContreras@mednet.ucla.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- University of California
-
Contact:
- Clemence Bonnet, MD
- Phone Number: 310-794-7813
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Main inclusion Criteria:
- Male or female ≥18 years of age.
- Best corrected visual acuity in the affected eye of 20/200 or less.
- Documentation of a LSCD diagnosis and the central cornea is affected.
- Absence of lagophthalmos and eyelid abnormality
- Adequate forniceal depth is ≥ 5 mm.
- LSCD fails to resolve by surgical treatments of the ocular surface during the previous 6 months of screening visit.
- If the etiology of LSCD is due to chemical injury, a minimal interval of 1 year since the initial chemical injury is required.
- A Schirmer test result at 5 minute of ≥5 mm of wetting.
- Absence of active infectious keratitis in either eye at the Enrollment Visit.
- Have a life expectancy ≥ 2 years after enrollment.
Main exclusion Criteria:
- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
- Exposure keratopathy or lagophthalmos of the study eye.
- Persistent severe ocular surface inflammation and/or meibomian gland dysfunction
- Chemical injury occurred less than 12 months ago.
- Presence of ocular surface tumor.
- Uncontrolled diabetes with last hemoglobin A1C (HgA1C) >8.5.
- Presence of known allergies to any of the cLSC components.
- Current participation in another simultaneous medical investigation or trial.
- Unable to be compliant with or complete the requirements of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cultivated Limbal Stem-Cells (cLSC)
One dose of cultivated limbal stem-cells (cLSC), size between 7.6 to 15 mm in the average diameter.
|
Transplantation of cLSC
|
Active Comparator: Scleral Contact Lens Device (SCL)
Scleral contact lens device (SCL) will be fitted to stabilize and improve ocular surface.
|
Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of cLSC Transplant pertaining to Infection and/or Corneal Perforation
Time Frame: 12 months for all participants
|
Safety assessed by incidence of Serious Adverse Events (SAEs) directly related to cLSC: infection and/or corneal perforation.
|
12 months for all participants
|
Feasibility of cLSC Transplant pertaining to Manufacturing meeting Release Criteria
Time Frame: 12 months for all participants
|
Feasibility assessed by successful manufacturing of cLSC from biopsy that meets release criteria.
|
12 months for all participants
|
Feasibility of cLSC Transplant pertaining to Manufacturing without Contamination
Time Frame: 12 months for all participants
|
Feasibility assessed by successful cLSC manufacturing without contamination.
|
12 months for all participants
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the Area of Corneal Epithelial Defect
Time Frame: At 6 months and 12 months in both cLSC and the control groups
|
Evaluate changes in the area of corneal epithelial defect (ED) or lack of ED.
|
At 6 months and 12 months in both cLSC and the control groups
|
Changes in the Clinical Score
Time Frame: At 6 months and 12 months in both cLSC and the control groups
|
Evaluate changes in the clinical score determined by slit lamp examination using fluorescein staining and confocal imaging.
|
At 6 months and 12 months in both cLSC and the control groups
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sophie Deng, MD, PhD, Stein Eye Institute UCLA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 30, 2020
Primary Completion (Estimated)
April 30, 2024
Study Completion (Estimated)
May 31, 2024
Study Registration Dates
First Submitted
February 21, 2019
First Submitted That Met QC Criteria
May 17, 2019
First Posted (Actual)
May 21, 2019
Study Record Updates
Last Update Posted (Estimated)
December 6, 2023
Last Update Submitted That Met QC Criteria
December 5, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V001
- R01EY021797 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Limbal Stem-cell Deficiency
-
National Taiwan University HospitalRecruiting
-
CHU de Quebec-Universite LavalRecruitingLimbal Stem Cell DeficiencyCanada
-
Siriraj HospitalOsaka UniversityCompletedLimbal Stem-cell DeficiencyThailand
-
CellSeed France S.A.R.L.FGK Clinical Research GmbHWithdrawnLimbal Stem Cell DeficiencyGermany
-
The S.N. Fyodorov Eye Microsurgery State InstitutionRecruitingLimbal Stem-cell DeficiencyRussian Federation
-
National Taiwan University HospitalRecruiting
-
Klinikum Chemnitz gGmbHInstitute of Anatomy TU DresdenCompletedLimbal Stem-cell Deficiency
-
Royan InstituteSmall Business Developing Center; Labafi Nejad Eye Research CenterCompletedLimbal Stem Cell DeficiencyIran, Islamic Republic of
-
Royan InstituteCompletedLimbal Stem Cell Deficiency (LSCD)
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & ServicesActive, not recruitingLimbal Stem Cell DeficiencyUnited States, Germany
Clinical Trials on cLSC
-
Ruijin HospitalChanghai Hospital; Fudan University; RenJi HospitalWithdrawnRectal Diseases | Colorectal Cancer | Rectal Cancer | Rectal Neoplasms | Colon Cancer | Colonic Neoplasms | Colon DiseaseChina